Products - Headaches | Topic | NICE

Showing 15 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Atogepant for preventing migraine (TA973)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Rimegepant for treating migraine (TA919)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Rimegepant for preventing migraine (TA906)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2023
Eptinezumab for preventing migraine (TA871)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 March 2023
Fremanezumab for preventing migraine (TA764)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Erenumab for preventing migraine (TA682)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Galcanezumab for preventing migraine (TA659)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Tocilizumab for treating giant cell arteritis (TA518)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 April 2018
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
STS101 for treating acute migraine TS ID 11782
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Galcanezumab for migraine TS ID 10663
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Upadacitinib for treating giant cell arteritis [ID6299]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Botulinum toxin type A for preventing episodic migraine ID 6450
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zavegepant for treating acute migraine TSID 11998
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC